Lonidamine

Drug Profile

Lonidamine

Alternative Names: TH-070

Latest Information Update: 04 Sep 2006

Price : $50

At a glance

  • Originator Threshold Pharmaceuticals
  • Class Cytostatics; Indazoles; Small molecules
  • Mechanism of Action Glycolysis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 04 Sep 2006 Interim results from discontinued phase II and phase III clinical trials in patients with benign prostatic hyperplasia have been added to the adverse events and Mens Health therapeutic trials sections
  • 17 Jul 2006 Discontinued - Phase-III for Benign prostatic hyperplasia in Europe (PO)
  • 17 Jul 2006 Discontinued - Phase-II for Benign prostatic hyperplasia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top